Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4

Conditions

Leukemia, Myeloid, Acute 4Pathologic Complete Response 1Leukemia 1

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 29Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13Ipilimumab 12Capecitabine 12durvalumab 11Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Azacitidine × Clear all
NCT02993523 2026-05-15

Viale-a

AbbVie

Phase 3 Completed
443 enrolled 14 charts 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Astellas Pharma Inc

Phase 3 Completed
371 enrolled 36 charts 2 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

Servier

Phase 3 Active not recruiting
146 enrolled 11 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Celgene

Phase 3 Completed
472 enrolled 24 charts 1 FDA
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡